ERYTECH will present a new vesiculation approach at the 24th Congress of the European Red Blood Cell Society (ERCS) – 04/04/2022 at 07:30

ERYTECH

will present a new approach to vesiculation

to

24

th

Congress

of the society

European

Red Blood Cells

(ERCS)

• Oral presentation
  
  

  of the study of
  
  

  feasibility of producing extracellular vesicles c
  
  

  containing a therapeutic substance
  
  

  ,
  
  

  issues
  
  

  red blood cells
  
  

  previously charged
  
  

  s
  
  

  using the ERYCAPS® process
  
  

  :
  
  

  ERYCEV
  
  
  

  TM
  
  

Lyon, France),

and Cambridge, MA (U

.S.)

,

the

April 4

202

2

–

ERYTECH

Pharmaceuticals (Euronext

:

ERYP

; Nasdaq

:

ERYP),

clinical-stage biopharmaceutical company that develops innovative therapies by encapsulating drugs in red blood cells

(GR)

,

announcement

today

the presentation of

her

new approach to vesiculation of

GR

at 24

th

Congress of the European Red Blood Cell Society (ERCS)

taking place from 7 to 11 April 2022

at

Gazzada

Schian

not

oh

,

in Italy.

Oral presentation

: evaluation of production methods, characterization and biological activity of extracellular vesicles derived from red blood cells (RBCEVs) containing an active molecule

Date hour

:

Saturday April 9 at 11:30 a.m., during the session “

Technology: Red blood cells as carriers, cultured red blood cells, blood banks

»

Red blood cell-derived extracellular vesicles (RBCEVs) naturally form during senescence and storage of mature red blood cells. Their use as a drug delivery system (DDS) appears promising due to their intrinsic properties: small size, wide range of potential delivery routes, natural targeting of immune cells, absence of nucleic acids, and ready availability of RBCs for their output. The vesiculation of RBCs previously loaded with therapeutic substances by the ERYCAPS® process suggests the potential for the production of extracellular vesicles derived from loaded RBCs for the development of new therapeutic approaches.

Françoise Horand, Director of R&D Operations

comments

: “

We are pleased

to share the work of our team and our collaborators

at the next ERCS congress

and in particular to be able to present the ERYCEV technology

TM

based on usage

innovation of our patented ERYCAPS platform

®

to produce extracellular vesicles

derived

red blood cells, loaded

and

s of active substances.

I

he first results of the characterization of the in vitro biological activity of these

RBCEV

s

pre

alway

charge

and

s

are very encouraging and

allows

and

nt to consider

future application in immune modulation.

»

Gil Beyen

live

had

r

General of ERYTECH

,

adds

: “

I

the results that will be presented

at the congress

of the ERCS underline the versatility and the great potential of our ERYCAPS® platform

.

We look forward to discussing

u potential to

development

with scientists specializing in

Red cells

and U.S

we will work to provide updates

on

ERYCEV

TM

according to

I

are advanced

from the program. »

ERYTECH and its researchers will also participate in the Poster session on April 8 to present

I

he capabilities of the ERYCAPS® therapeutic platform

and at the session “

RBC

diseases

» to discuss the work carried out in collaboration with the LIBM (Interuniversity Laboratory of Biology of Motricity of Lyon)

.

About ERYTECH and eryaspase

(GRASPA®)

www.erytech.com

Founded in Lyon in 2004, ERYTECH is a clinical-stage biopharmaceutical company that develops innovative therapies based on red blood cells to fight cancers and orphan diseases. Leveraging its proprietary ERYCAPS® platform, an innovative technology for encapsulating drugs in red blood cells, ERYTECH is developing a portfolio of product candidates targeting markets with significant unmet medical needs. ERYTECH focuses primarily on the development of products targeting metabolic disturbances in cancer cells, in order to deprive them of the amino acids necessary for their growth and survival.

The Company’s lead product, eryaspase (GRASPA®), consisting of L-asparaginase encapsulated in red blood cells from donors, addresses the altered asparagine and glutamine metabolism of cancer cells. The proof of concept of eryaspase as a metabolic agent against cancer has been established in different trials on acute lymphoblastic leukemia (ALL) and pancreatic cancer. A phase 2 investigator-sponsored study (IST) evaluating the use of eryaspase in patients with ALL who developed hypersensitivity reactions to pegylated asparaginase recently showed positive results, based on which the Company intends to file for approval in the United States and potentially in other territories. Eryaspase is also being evaluated in an investigator-sponsored Phase 1 clinical trial for the first-line treatment of advanced pancreatic cancer.

Eryaspase has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for the treatment of patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity reactions to pegylated asparaginase and for the treatment of cancer of the advanced pancreas. The FDA and the European Medicines Agency have granted eryaspase orphan drug status for the treatment of ALL and pancreatic cancer.

ERYTECH produces its drug candidates for the treatment of patients in Europe at its GMP-compliant production site in Lyon, France, and for patients in the United States at its GMP-compliant production site in New Jersey, USA. Eryaspase is not approved in any country.

ERYTECH is listed on the Nasdaq Global Select Market in the United States (symbol: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135; symbol: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indices.

CONTACTS

Forward-looking statements

This press release contains forward-looking statements, including with respect to the clinical development and regulatory strategy of eryaspase, including the timeline for BLA’s potential FDA submission for the treatment of acute lymphoblastic leukemia, the ability of the company to obtain regulatory approval for the treatment of patients with acute lymphoblastic leukemia who have developed hypersensitivity reactions to asparaginase derived from

E.coli

, the company’s ability to expand the eryaspase indication field, the company’s ability to obtain additional funds under the OCABSA financing agreement or other financing attempts, and the anticipated cash flow of the society. Some of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “projects”, “plans”, “seeks”, “estimates”, “may”, “wants” and “continues” and other similar expressions. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may not prove to be correct. Actual events are difficult to predict and may depend on factors beyond the Company’s control. With respect to the pipeline of product candidates, there can be no assurance that such product candidates will receive the necessary regulatory approvals or achieve commercial success. The Company’s expectations regarding the effects of COVID-19 on the Company’s testing and development may be incorrect. Accordingly, actual results and timing may differ materially from any anticipated future results, performance or achievements as expressed or implied by such statements, forecasts and estimates. The documents filed by ERYTECH with the Autorité des Marchés Financiers (AMF) and the Securities and Exchange Commission (SEC), including the Company’s 2020 Universal Registration Document registered with the AMF on March 8, 2021, Company’s Annual Report (Form 20-F) filed with the SEC on March 8, 2021 and future Company filings and reports, describe such risks and uncertainties. Given these uncertainties, no representation is made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. In addition, forward-looking statements, forecasts and estimates speak only as of the date of this release. Readers are therefore cautioned not to place undue reliance on these forward-looking statements. ERYTECH disclaims any obligation to update such forward-looking statements, forecasts or estimates to reflect any change in the company’s expectations with respect thereto, or any change in events, conditions or circumstances on which such statements, forecasts or estimates are based, except as required by law. Furthermore, the COVID-19 pandemic and all the measures that have been taken to mitigate its impacts are negatively affecting the economy, for a duration and severity that remain uncertain. Government measures to stabilize the situation will not be able to completely mitigate the consequences. The extent and duration of these impacts on the Company’s business and results are highly uncertain, and these impacts may in particular affect the Company’s clinical developments, as well as its supply chain. Factors impacting the Company’s business and results include the duration and extent of the pandemic, the extent of mandatory pandemic containment and mitigation measures, and the consequences of the pandemic on the economy in general. The pandemic could have negative effects on the company’s activity, the progress of its projects and its financial results for a longer period.

Attachment

• CP_ERYTECH_presentation ERCS_04422_FR